Loading…
EQ
Equillium, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 29446K106
$2.39-2.45%Price as of Aug 29, 18:37 UTC · updated once a day, after the close
Key metrics
- Market cap
- $151.55M
- P/E
- —
- Forward P/E
- —
- P/B
- 2.7x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.09
- ROE
- -58.98%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 1.81
- 52-week high
- $3.54
- 52-week low
- $0.76
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -73.5% over 5Y.
today you would have $244.87▼ -75.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 8 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $1.55 | $0.75 | $0.72 | $1.06 | $3.77 | $5.35 | $3.38 | $8.16 | |
| P/S | 0.7x | — | 0.6x | 0.7x | 2.3x | — | — | — | — |
| P/B | 1.7x | 3.4x | 1.4x | 1.1x | 1.1x | 1.9x |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| INDPIndaptus Therapeutics, Inc. | $1.14 | — | 13.4x | — | -318.04% | $151.9M |
| CDXSCodexis Inc | $1.38 | — | 3.8x | — | -69.36% | $151.12M |
| KRROKorro Bio, Inc. | $10.34 | — | 1.5x | — | -97.69% | $152.26M |
| CRBPCorbus Pharmaceuticals Holdings, Inc. | $7.88 |
About the company
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
- 14
- La Jolla, United States
Company description provided by Yahoo Finance.